Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial (clinicaltrials.gov) - Oct 22, 2026 - P2 | N=31 | Active, not recruiting | Sponsor: Alliance for Clinical Trials in Oncology | Trial completion date: Oct 2033 ➔ Apr 2033 | Trial primary completion date: Mar 2028 ➔ Oct 2027
Trial completion date • Trial primary completion date • Endocrine Cancer • Gastrointestinal Neuroendocrine Carcinoma • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR
|